Assessment of prognostic value FOXA1 Expression in breast carcinoma after neoadjuvant chemotherapy: Immunohistochemically Study

Document Type : Original Article

Authors

1 Department of pathology, Faculty of Medicine, Benha University

2 Department of pathology, Medical Research Institute, Alexandria University

3 MBBCH, master degree of pathology, Assistant lecturer of pathology, Medical Research Institute- Alexandria University

Abstract

Background: Breast carcinoma is the most common malignant tumor and the leading cause of carcinoma death in women. Aim and objectives: to determine the expression of FOXA1 in breast carcinoma, to correlate the expression of FOXA1 with hormonal receptors (ER and PR), Her2neu, Ki67 and pathological response to chemotherapy. Patient and method: This retrospective study was carried on 100 cases included seven cases with bilateral breast cancer, eighty-six cases IDC, five cases ILC and fifty-six cases with positive axillary lymph nodes metastasis. It was performed on formalin-fixed paraffin-embedded tissue blocks of specimens, collected from Benha Pathology Department, Faculty of Medicine, Benha University, from the years (2013- 2019). Result: Concerning the pathological response were found that (40) cases showed complete pathological response and (13) cases has no pathological response out of them FOXA1 positivity (44 and 7 cases respectively). While for (ER), (89) cases are positive out of them (74) case FOXA1 positive, and (PR), (80) cases positive, FOXA1 positivity (68) out of them, however Her-2neu negative cases were (48) from them (41) case are FOXA1 positive. Fore Ki-67, fourteen (14) cases show low scoring, while (31) cases has intermediate score and (55) cases has high scoring, FOXA1 positivity out of them (14, 31, 33 cases respectively). Conclusion: FOXA1 is a marker of good prognosis in breast cancer as FOXA1 expression associated with complete pathological response, positive hormone receptors and low-intermediate Ki67.

Keywords